Has Madelyn Duty received payments from drug or device companies?

Yes. Drug and device makers reported $10,316 in general payments to Madelyn Duty across 437 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Madelyn Duty did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Madelyn Duty come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Madelyn Duty

Family · North Venice, FLNPI 1124742770

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 90.9% of the total across 437 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 9.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,725, 9.2 times the $405 reported in 2022. Among family clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$10,316in general payments, 2019–2025

Across 437 payments — averaging $23.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$945
E.r. Squibb & Sons, L.L.C.$706
Novartis$630
Merck$582
Incyte Corporation$563
Daiichi Sankyo Inc.$562
plus $6K from 54 others

What the payments were for

Food & beverage$9,38191%
Education$9349%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca(2 entities)	46	$945
E.r. Squibb & Sons, L.L.C.	38	$706
Novartis	34	$630
Merck	24	$582
Incyte Corporation	21	$563
Daiichi Sankyo Inc.	21	$562
Gilead(2 entities)	14	$452
Johnson & Johnson	17	$430
Takeda Pharmaceuticals U.S.A., Inc.	15	$372
Pfizer	16	$353
Seagen Inc.	5	$335
Lilly USA, LLC	10	$290
Eisai Inc.	13	$279
GSK	12	$271
Bayer	15	$260
Bristol Myers Squibb	8	$241
Sobi, Inc	12	$234
Beigene USA, Inc.	9	$233
Ipsen Biopharmaceuticals, Inc	4	$215
Exelixis Inc.	3	$139
AbbVie	6	$124
Astellas Pharma US Inc	6	$119
Jazz Pharmaceuticals Inc.	4	$117
Kyowa Kirin, Inc.	5	$112
Pharmaessentia USA Corporation	2	$105
Puma Biotechnology, Inc.	5	$100
Regeneron Healthcare Solutions, Inc.	3	$90
Sumitomo Pharma America, Inc.	5	$88
Amgen	4	$85
Pharmacosmos Therapeutics Inc.	4	$73
Array Biopharma Inc	4	$72
AVEO Pharmaceuticals, Inc.	3	$62
Beone Medicines USA, Inc.	3	$62
Legend Biotech USA Inc.	2	$60
EMD Serono, Inc.	3	$59
Dendreon Pharmaceuticals LLC	2	$57
Genentech USA, Inc.	3	$56
Genmab U.S., Inc.	2	$54
Stemline Therapeutics Inc.	2	$53
Boehringer Ingelheim	2	$50
Syndax Pharmaceuticals, Inc.	2	$47
Iovance Biotherapeutics, Inc.	2	$46
Agios Pharmaceuticals, Inc.	2	$45
Geron Corporation	2	$41
Karyopharm Therapeutics Inc.	2	$39
Morphosys, US Inc.	2	$38
Epizyme, Inc.	2	$37
Sanofi	2	$36
Pharmacyclics LLC, An Abbvie Company	2	$33
Tersera Therapeutics LLC	1	$32
Immunogen, Inc.	1	$28
Deciphera Pharmaceuticals Inc.	1	$25
Rigel Pharmaceuticals, Inc.	1	$24
G1 Therapeutics, Inc.	1	$24
Tolmar Pharmaceuticals, Inc.	1	$22
Servier Pharmaceuticals LLC	1	$21
Recordati_rare_diseases_inc.	1	$20
Blueprint Medicines Corporation	1	$19
Mirati Therapeutics, Inc.	1	$19
Alnylam Pharmaceuticals Inc.	1	$15

How this compares

$10,316 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.

See all family providers in Florida →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Hydroxyurea	27	$487
Acyclovir	11	$346
Ondansetron OdtOndansetron	13	$322
Anastrozole	14	$274
Letrozole	14	$166
Gabapentin	12	$95
Prednisone	14	$72

Paid to pharmacies, not to this prescriber.

Other family in North Venice

Lewis HarringtonTampa$954K
Danielle PharesFt Lauderdale$713K
Donna OrtizOrlando$417K
Patrick SzarazMiami$327K
Deena RodneyMaitland$323K
Yamila MelendezMiami$212K
Holly BoydLand O Lakes$200K
Rachael BuschLoxahatchee$189K
Victor Tatis de la NuezMiramar$161K
Ronda CrewsJax Bch$155K

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →